Medical News

Filed under: Drug, Liver Cancer

Nexavar, a pharmaceutical drug designed to treat liver cancer, had a late-stage trial recently cut off and disbanded.

But, the reason is not what you think: the trial was ended because the results of patients using the drug were all so positive that a further continuation of the trial was not needed.

The trial (which was classified “Phase III” — the ‘final’ stage) was conducted on over 200 patients in China, Korea and Taiwan. All patients took Nexavar and all were suffering from hepatocellular carcinoma — the most common liver cancer.

Still, it’s odd that any trials were ended due to excellent results. Even if that is so, shouldn’t all drugs complete a start-to-finish trial period, regardless of success rate?

Read | Permalink | Email this | Linking Blogs | Comments

Original post by Brian White